“Moral Distress” Has Arrived On Health Care’s Stoop

By MIKE MAGEE When Andrew Jameton, a Nursing Professor at the Department of Mental Health and Community Nursing at UCSF in 1984 published “Nursing Practice: The Ethical Issues”, the term “Moral Distress” was a novel term in clinical health care. It focused primarily on “care that they were expected to provide but ethically opposed.” Over…

Read More

Links

How do companies decide which drugs to develop?“attending a more selective college causally reduces obesity”28% of patients with HIV were covered by MedicareThe AI Scientist + End-to-end causal effect estimation Development approval timelines and new housing supply in LA

Read More

Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline

Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022. The post Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline appeared first on MedCity News.

Read More